NCT04588428Phase 2Completed

Safety, Tolerability and Immunogenicity of INO-4700 for MERS-CoV in Healthy Volunteers

Study sponsor: Inovio Pharmaceuticals

Primary completion is the date data collection ends for the main study measures, not when results are published.

Primary completion2023-01-19Actual
Enrollment · participants192Actual
Source updated2026-01-22Last update listed in the registry record

Changes to this trial

Last 12 months
Filters
Clear filters

· 1 field changed

Main study measure wording changed

Text changed; whether the study measures changed has not been verified. Saved text may be shortened.

Before: Measure: Frequency of Adverse Events in Part 1 Measure: Percentage of Participants with Adverse Events in Part 1 Measure: Frequency of Injection Site Reactions in Part 1 Measure: Percentage of Participants with Injection Site Reactions in Part 1 Measure: Frequency of Adverse Events of Special Interest (AESIs) in Part 1 Measure: Percentage of Participants with Adverse Events of Special Interest (AESIs) in Part 1 Measure: Geometric Mean Titers (GMTs) of MERS-CoV Antigen Specific Binding Antibodies in Part 1 Measure: Percentage MERS-CoV Antigen Specific Neutralizing Antibodies in Part 1 Measure: Percentage Antigen Specific Cellular Immune Response in Part 1 Measure: Percentage of Seroconverted Participants in Part 1 Measure: Percentage of Participants with Overall Immune Response in Part 1 Measure: Frequency of Adverse Events in Part 2 Measure: Percentage of Participants with Adverse Events in Part 2 Measure: Frequency of Injection Site Reactions in Part 2 Measure: Percentage of Participants with Injection Site Reactions in Part 2 Measure: Frequency of Adverse Events of Special Interest (AESIs) in Part 2 Measure: Percentage of Participants with Adverse Events of Special Interest (AESIs) in Part 2 Measure: Geometric Mean Titers (GMTs) of MERS-CoV Antigen Specific Binding Antibodies in Part 2 Measure: Percentage MERS-CoV Antigen Specific Neutralizing Antibodies in Part 2 Measure: Percentage Antigen Specific Cellular Immune Response in Part 2 Measure: Percentage of Seroconverted Participants in Part 2 Measure: Percentage of Participants with Overall Immune Response in Part 2. After: Measure: Part 1: Percentage of Participants With Treatment-emergent Adverse Events (TEAEs), Graded by Severity, and Treatment-related AEs Measure: Part 1: Percentage of Participants With Injection Site Reactions Measure: Part 1: Percentage of Participants With Adverse Events of Special Interest (AESIs) Measure: Part 1: Geometric Mean Concentration (GMC) of INO-4700 Antigen Specific Binding Antibody at Week 6 Measure: Part 1: Geometric Mean Fold Rise (GMFR) of INO-4700 Antigen Specific Binding Antibody at Week 6 Measure: Part 1: Geometric Mean Concentration (GMC) of INO-4700 Antigen Specific Binding Antibody at Week 10 Measure: Part 1: Geometric Mean Fold Rise (GMFR) of INO-4700 Antigen Specific Binding Antibody at Week 10 Measure: Part 1: Percentage Neutralizing Antibody Responders at Week 6 Measure: Part 1: Percentage Neutralizing Antibody Responders at Week 10 Measure: Part 1: Percentage of Antigen Specific Cellular Immune Responders at Week 6 Measure: Part 1: Percentage of Antigen Specific Cellular Immune Responders at Week 10 Measure: Part 2: Percentage of Participants With Adverse Events Measure: Part 2: Percentage of Participants With Injection Site Reactions Measure: Part 2: Percentage of Participants With Adverse Events of Special Interest (AESIs) Measure: Part 2: Geometric Mean Concentration (GMC) of INO-4700 Antigen Specific Binding Antibody Measure: Part 2: Percentage Neutralizing Antibody Responders Measure: Part 2: Percentage of Antigen Specific Cellular Immune Responders.

Check registry source